Agios Pharmaceuticals (NASDAQ:AGIO) has been in the news a lot lately, and the news has been generally positive for the stock. It closed on April 8, 2021 at $52.92 per share. That is down just 10% from its
Agios A Buy For Rare Disease Focus, Stock Buyback
Summary
- Agios is repurchasing stock from Bristol-Myers.
- Agios just sold its oncology franchise to Servier.
- Focus on Mitapivat and rare diseases has risks but is likely good for shareholders.
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.
Analyst’s Disclosure:I am/we are long AGIO, BMY. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.